

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	HealthCo Healthcare and Wellness REIT (ASX: HCW)
<b>ARSN</b>	652 057 639

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Christopher Graham Roberts
<b>Date of last notice</b>	6 March 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<ul style="list-style-type: none"> <li>• Romaxis Pty Ltd (ACN 126 199 924) as trustee for &lt;Roblis Super Fund A/C&gt; (of which Christopher Roberts is a beneficiary)</li> <li>• Acemed Pty Ltd (ACN 078 477 193) as trustee for &lt;MAXIS A/C&gt; (of which Christopher Roberts is a beneficiary)</li> </ul>
<b>Date of change</b>	A. 18 April 2023 B. 18 April 2023
<b>No. of securities held prior to change</b>	<p>Direct interest: 9,636 ordinary units</p> <p>Indirect interest:</p> <ul style="list-style-type: none"> <li>• Romaxis Pty Ltd (ACN 126 199 924) as trustee for &lt;Roblis Super Fund A/C&gt; (of which Christopher Roberts is a beneficiary) – 350,000 ordinary units</li> <li>• Acemed Pty Ltd (ACN 078 477 193) as trustee for &lt;MAXIS A/C&gt; (of which Christopher Roberts is a beneficiary) – 310,000 ordinary units</li> </ul>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	Fully paid ordinary units
<b>Number acquired</b>	A. 184,209 ordinary units acquired by Romaxis Pty Ltd as trustee for <Roblis Super Fund A/C> B. 163,156 ordinary units acquired by Acemed Pty Ltd as trustee for <MAXIS A/C>
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	A. \$1.35 per ordinary unit B. \$1.35 per ordinary unit
<b>No. of securities held after change</b>	Direct interest: 9,636 ordinary units  Indirect interest: <ul style="list-style-type: none"> <li>• Romaxis Pty Ltd (ACN 126 199 924) as trustee for &lt;Roblis Super Fund A/C&gt; (of which Christopher Roberts is a beneficiary) – 534,209 ordinary units</li> <li>• Acemed Pty Ltd (ACN 078 477 193) as trustee for &lt;MAXIS A/C&gt; (of which Christopher Roberts is a beneficiary) – 473,156 ordinary units</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Both acquisitions are issues of fully paid ordinary units acquired under the early retail component of the accelerated, pro-rata non-renounceable entitlement offer announced by HCW on 30 March 2023.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.